Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference
Express News | Acumen Pharmaceuticals Inc : UBS Cuts Target Price to $6 From $14
UBS Maintains Buy on Acumen Pharmaceuticals, Lowers Price Target to $6
Acument Pharmaceuticals Shares Are Trading Lower. The Stock May Be Moving on Continued Weakness After the Company Reported Worse-than-expected Q2 EPS Results Yesterday.
BTIG Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Maintains Target Price $11
BTIG analyst Thomas Shrader maintains $Acumen Pharmaceuticals(ABOS.US)$ with a buy rating, and maintains the target price at $11.According to TipRanks data, the analyst has a success rate of 38.9%
H.C. Wainwright Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Maintains Target Price $15
H.C. Wainwright analyst Andrew Fein maintains $Acumen Pharmaceuticals(ABOS.US)$ with a buy rating, and maintains the target price at $15.According to TipRanks data, the analyst has a success rate of 4
Buy Rating for Acumen Pharmaceuticals Backed by Promising Alzheimer's Treatment Advances and Strong Financials
HC Wainwright & Co. Reiterates Buy on Acumen Pharmaceuticals, Maintains $15 Price Target
Acumen Pharmaceuticals Analyst Ratings
Q2 2024 Acumen Pharmaceuticals Inc Earnings Call
Acumen Pharmaceuticals | 10-Q: Q2 2024 Earnings Report
Earnings Call Summary | Acumen Pharmaceuticals(ABOS.US) Q2 2024 Earnings Conference
Acumen Pharmaceuticals, Inc. (ABOS) Q2 2024 Earnings Call Transcript
Acumen Pharmaceuticals Unveils Updated Corporate Presentation and Financials
Express News | Acumen Pharmaceuticals Inc Q2 Shr View $-0.28 -- LSEG IBES Data
Express News | Acumen Pharmaceuticals: Qtrly Shr Loss $0.34
Express News | Acumen Pharmaceuticals: Current Cash, Equivalents, Marketable Securities to Support Current Clinical and Operational Activities Into H1 of 2027
Acumen Pharmaceuticals Q2 2024 GAAP EPS $(0.34) Misses $(0.28) Estimate
Express News | Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Highlights
Acumen Pharmaceuticals 2Q Loss $20.5M >ABOS